Chronic pancreatitis: Multicentre prospective data collection and analysis by the Hungarian Pancreatic Study Group

Ákos Szűcs1, Tamás Marjai1, Andrea Szentesi2,3, Nelli Farkas4, Andrea Pániczky5, György Nagy6, Balázs Kui7, Tamás Takács3, László Czakó3, Zoltán Szepes3, Balázs Csaba Németh8, Áron Vincze9, Gabriella Pár9, Imre Szabó7, Patricia Sarlós3, Anita Illés7, Sziárd Gödi6, Ferenc Izbéki10, Judit Gervain10, Adrienn Halász3, Gyula Farkas10, László Leindler10, Dezső Kelemen11, Róbert Papp11, Richárd Szmola12, Mátra Varga13, József Hamvas14, János Novák15, Barnabás Bod16, Miklós Sahin-Tóth17, Péter Hegyi2,3,8,18 *, on behalf of the Hungarian Pancreatic Study Group3

1 First Department of Surgery, Semmelweis University, Budapest, Hungary, 2 Institute for Translational Medicine, University of Pécs, Pécs, Hungary, 3 First Department of Medicine, University of Szeged, Szeged, Hungary, 4 Institute of Bioanalysis, University of Pécs, Pécs, Hungary, 5 Heim Pál Children’s Hospital, Budapest, Hungary, 6 Second Department of Internal Medicine, University of Debrecen, Debrecen, Hungary, 7 Division of Gastroenterology, First Department of Medicine, University of Pécs, Pécs, Hungary, 8 Division of Translational Medicine, First Department of Medicine, University of Pécs, Pécs, Hungary, 9 Szent György University Teaching Hospital of Fejér County, Székesfehérvár, Hungary, 10 Department of Surgery, University of Szeged, Szeged, Hungary, 11 Department of Surgery, University of Pécs, Pécs, Hungary, 12 Department of Interventional Gastroenterology, National Institute of Oncology, Budapest, Hungary, 13 Dr. Réthyi Pál Hospital, Békéscsaba, Hungary, 14 Bajcsy-Zsilinszky Hospital, Budapest, Hungary, 15 Pándy Kálmán Hospital of Békés County, Gyula, Hungary, 16 Dr. Bugyi István Hospital, Szentes, Hungary, 17 Center for Exocrine Disorders, Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, Massachusetts, United States of America, 18 Hungarian Academy of Sciences—University of Szeged, Momentum Gastroenterology Multidisciplinary Research Group, Szeged, Hungary

Membership of the Hungarian Pancreatic Study Group can be found in the Acknowledgments.

* hegyi.peter@med.u-szeged.hu

Abstract

Introduction

Chronic pancreatitis is an inflammatory disease associated with structural and functional damage to the pancreas, causing pain, maldigestion and weight loss and thus worsening the quality of life.

Aims and methods

Our aim was to find correlations from a multicentre database representing the epidemiological traits, diagnosis and treatment of the disease in Hungary. The Hungarian Pancreatic Study Group collected data prospectively from 2012 to 2014 on patients suffering from chronic pancreatitis. Statistical analysis was performed on different questions.

Results

Data on 229 patients (74% male and 26% female) were uploaded from 14 centres. Daily alcohol consumption was present in the aetiology of 56% of the patients. 66% of the patients...
were previously treated for acute exacerbation. One third of the patients had had previous endoscopic or surgical interventions. Pain was present in 69% of the cases, endocrine insufficiency in 33%, diarrhoea in 13% and weight loss in 39%. Diagnosis was confirmed with US (80%), CT scan (52%), MRI-MRCP (6%), ERCP (39%), and EUS (7.4%). A functional test was carried out in 5% of the patients. In 31% of the cases, an endoscopic intervention was performed with the need for re-intervention in 5%. Further elective surgical intervention was necessitated in 44% of endoscopies. 20% of the registered patients were primarily treated with surgery. The biliary complication rate for surgery was significantly smaller (2%) than endoscopy (27%); however, pancreatic complications were higher in the patients treated with surgery. Patients who smoked regularly needed significantly more surgical intervention after endoscopy (66.7% vs. 26.9%, p = 0.002) than non-smokers, and the ratio of surgical intervention alone was also significantly higher (27.3% vs. 10.8%, p = 0.004). The ratio of surgery in patients who smoked and drank was significantly higher (30.09% vs. 12.5%, p = 0.012) than in abstinent and non-smoking patients, similarly to the need for further surgical intervention after endoscopic treatment (71.43% vs. 27.78%, p = 0.004).

Conclusions

According to the data analysed, the epidemiological data and the aetiological factors in our cohort differ little from European trends. The study highlighted the overuse of ERCP as a diagnostic modality and the low ratio of use of endoscopic ultrasonography. The results proved that alcohol consumption and smoking represent risk factors for the increased need for surgical intervention. Chronic pancreatitis should be treated by multidisciplinary consensus grounded in evidence-based medicine.

Introduction

Chronic pancreatitis (CP) is a progressive inflammatory disease associated with structural and functional damage to the pancreas, causing pain, maldigestion and weight loss and thus worsening the quality of life. The clinical presentation is variable depending on the stage of the disease. The early stage disease (stage A) is dominated by recurrent clinical acute pancreatitis. In stage B, constant pain occurs with local complications from jaundice to pancreatic fistula, but exocrine and endocrine function is preserved. In end stage CP (stage C), pancreatic fibrosis leads to exocrine and/or endocrine function loss [1].

Although the pathomechanism of chronic pancreatitis is still poorly understood and evaluating a genetic predisposition and the effect of toxic agents (smoking and alcohol consumption) may open up potential for future research, the clinical features in the diagnosis and therapy ensure a great deal of evidence for lifelong management of the disease. Patients with chronic pancreatitis develop the clinical triad of abdominal pain and exocrine and endocrine pancreatic insufficiency. Despite the progressive fibrosis of the pancreatic tissue, the typical symptoms are not usually present, only in burn-out CP (after the loss of 90% of functioning pancreatic tissue) [2]. Frequently, only recurrent acute episodes show any evidence of the disease.

Though the diagnosis of CP can be obvious in advanced stage, confirming the disease in early stages without classical clinical symptoms is more challenging. Chronic pancreatitis is usually diagnosed with a combination of clinical presentation, imaging and pancreatic function
Due to the heterogeneous nature of the disease, a gold standard, universal treatment does not exist. The main goals of medical management of chronic pancreatitis are management of pain, exocrine and endocrine insufficiency, and treatment of possible complications, such as bleeding, biliary obstruction, pseudocyst formation or malignancy, requiring a personalized approach based on multidisciplinary decision-making.

Although numerous data are available on the clinical management of patients with CP, there is a lack of randomized controlled trials that provide strong evidence for individual diagnosis and treatment. There are only limited numbers of prospective cohorts available on the management of CP from Central Europe and no data from Hungary. The aim of our study was to collect data on patients suffering from chronic pancreatitis in a prospective manner and to find correlations from a multicentre database representing the epidemiological traits, diagnosis and treatment of the disease in Hungary.

**Patients and methods**

The study was approved by the Scientific and Research Ethics Committee of the Medical Research Council (22254-1/2012/EKU).

The Hungarian Pancreatic Study Group (HPSG) collected data on patients suffering from CP in a prospective and voluntary manner from 2012 to 2014 and enrolled 229 patients from 14 Hungarian centres. Patients were enrolled in an official healthcare centre by a clinician. The study was open to all centres which managed to provide valuable and precise data after signing a Letter of Intent to Join. The patient was informed of the purpose of the research and blood sampling, and the Patient Informed Consent Form was signed.

Researchers actively contributing to the Biobank and Registry or collaborating researchers can access samples and clinical data. Samples and data are available free of charge and should be used for research purposes only. An application should be made for access. Data are available for others to analyse upon request only.

Demographic data (including age and gender), possible risk factors (frequency and total amount of alcohol consumption, smoking, body mass index (BMI), history of previous pancreatic disease and diabetes mellitus), aetiology, symptoms and clinical signs (such as fever, pain, diarrhoea, jaundice and weight loss), laboratory parameters, imaging techniques, conservative and interventional therapy (such as endoscopy and surgery) and complications were collected and assessed. All data were collected after patients gave their informed consent. Data was collected using the web-based electronic data collection method at the National Pancreas Registry (OPR).

Diagnosis of the disease was determined by the uploader under thorough supervision of the HPSG based on the M-ANNHEIM classification. Patients with dubious diagnosis were excluded. Diagnosis was based on imaging tests including abdominal ultrasound, computed tomography, magnetic resonance imaging (MRI), endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasonography (EUS), including morphological findings typical of the different modalities. Relevant laboratory parameters were also collected. A cytological or histological diagnosis was performed using brush cytology during ERCP, fine needle aspiration biopsy (FNAB) or surgical biopsy/resection. The results of the pancreatic functional test were collected to prove the pancreatic exocrine insufficiency related to chronic pancreatitis.

The database included information on conservative and interventional treatment of CP. Data on enzyme substitution and anti-diabetic therapy were registered. The details of endoscopic treatment, such as stent type, number of interventions needed, complications and need
for further intervention, were recorded. Similarly, we determined the type of surgical operation and complications.

In order to be able to process data and reach relevant conclusions, we supplemented insufficient data load by using the term Quality of Data (QoD), a ratio of the adequate data number of a specific question and the number of patients involved in the cohort.

Authorship policy: Authorship was given to contributors who uploaded data to the registry on at least five patients and were involved in acquisition, analysis and interpretation of data. Contributors who provided data on fewer than five patients are mentioned in the acknowledgements.

**Statistical analysis**

For descriptive statistics, we calculated the case number, mean, standard deviation (SD), and minimum, median and maximum values in the case of continuous variables and the case number and percentage for categorical values. All statistical analyses were carried out with IBM SPSS Statistics v 20.0 (IBM Corporate, New York, USA). To compare the proportion between the subgroups, we used Pearson’s Chi-squared test or Fisher’s exact test. A p-value under 0.05 was considered statistically significant. Where the p-value was less than 0.1 but higher than 0.05, we suggested it as only a tendency.

**Results**

Two hundred and twenty-nine patients were enrolled in the study (Table 1). The mean age of the population was 54.63 years. There were more males than females (73.8% vs. 26.2%, respectively).

| Table 1. Patients’ epidemiological and anamnestic data. |
|--------------------------------------------------------|
| **Gender**                                             |
| Gender | Number of patients (n) | Percentage (%) |
| Male   | 169 | 73.8 |
| Female | 60 | 26.2 |

| **Alcohol consumption (QoD: 100%)** |
|------------------------------------|
| Alcohol consumption | Number of patients (n) | Percentage (%) |
| Never               | 85 | 37.3 |
| Occasionally        | 40 | 17.5 |
| Regularly           | 103 | 45.2 |

| **Smoking (QoD: 99%)** |
|------------------------|
| Smoking | Number of patients (n) | Percentage (%) |
| >20 cigarettes/day      | 56 | 24.7 |
| 10–20 cigarettes/day    | 72 | 31.9 |
| <10 cigarettes/day      | 15 | 6.6 |
| occasionally            | 4 | 1.8 |
| never                   | 79 | 35 |

| **Previous hospitalisation due to acute pancreatitis (QoD: 89%)** |
|---------------------------------------------------------------|
| Previous hospitalisation due to acute pancreatitis | Number of patients (n) | Percentage (%) |
| previous hospitalisation due to acute pancreatitis | 151 | 66 |

| **Previous endoscopic intervention (QoD: 100%)** |
|------------------------------------------------|
| Previous endoscopic intervention | Number of patients (n) | Percentage (%) |
| total                     | 72 | 31.4 |
| ERCP-EST                  | 39 | 54.2 |
| endobiliary stent         | 27 | 37.5 |
| Pancreatic duct stent stent | 0 | 0 |
| pseudocyst drainage       | 6 | 8.3 |

| **Previous surgical intervention (QoD: 100%)** |
|-----------------------------------------------|
| Previous surgical intervention | Number of patients (n) | Percentage (%) |
| total                             | 72 | 31.4 |
| decompression                    | 8 | 11.1 |
| drainage                          | 13 | 18.6 |
| resection                         | 20 | 27.7 |
| bilo-digestive anastomosis       | 21 | 29.1 |
| other                             | 10 | 13.9 |

doi:10.1371/journal.pone.0171420.t001
Risk factors and aetiology (QoD: 99%)

One hundred and forty-three patients (62.4%) were recorded as smoking regularly. Fifty-six patients (24.4%) smoked more than 20 cigarettes per day. Alcohol consumption was reported in 143 patients (62.4%), whereas 103 patients (56.7%) drank alcohol daily. Family history of CP was found in seven cases (3%). Genetic testing was only carried out in eight patients, of whom three proved positive (1.3%). Autoimmune origin was confirmed in one patient (0.4%). Recurrent acute pancreatitis was present in 75 patients (32.75%).

Symptoms and signs

The most frequent symptoms at the time of diagnosis in the period under examination was abdominal pain, which was present in 68.6% of all patients (QoD: 95%). Jaundice and fever were found in 11.5% and 11.35%, respectively (QoD: 100%).

Exocrine insufficiency (QoD: 100%)

35% of the patients reported 3.03 kg/month average weight loss. Diarrhoea was recorded in 12.66% of the patients.

Endocrine insufficiency (QoD: 100%)

Diabetes as an indicator of endocrine insufficiency was found on admission in 88 patients (38%) of the population under examination, of whom 37.5% were treated with insulin.

Anamnesis

The reason for previous hospital admissions was acute exacerbations in 66% of the cases (QoD: 89%). 72 (31%) patients underwent an endoscopic intervention (we performed ERCP and EST in 54.2% of them, endobiliary stent implantation in 37.5% and endoscopic pseudocyst drainage in 8.3%). Previously, 72 (31.4%) patients had a different kind of surgical intervention (of these, 11.1% underwent decompression, 18.6% were treated with surgical pseudocyst drainage, 27.7% had pancreatic resection and 29.1% underwent bilio-digestive anastomosis) (QoD: 100%).

Imaging (QoD: 100%)

As regards imaging examinations on admission, we performed abdominal ultrasonography in 184 patients (80%), CT scans in 120 (52%), MRI-MRCP in 14 (6.1%), diagnostic ERCP in 90 (39%) and endoscopic ultrasonography in 17 (7.4%). At least one US, CT or MRI was performed in 219 patients. Abnormalities characteristic of chronic pancreatitis based on the Cambridge criteria were found in 188 of these patients (86%). Similarly, in 95 patients who had MRCP or ERCP, 79 displayed typical abnormalities (83%). In 17 cases, EUS was performed, with only two cases showing normal gland structure (Table 2).

| Modality          | Number of patients (n) | Percentage (%) |
|-------------------|------------------------|----------------|
| **Ultrasonography** | 184                    | 80             |
| **CT Scan**       | 120                    | 52             |
| **MRI-MRCP**      | 14                     | 6.1            |
| **ERCP**          | 90                     | 39             |
| **EUS**           | 17                     | 7.4            |

doi:10.1371/journal.pone.0171420.t002
As regards functional tests, only (13) C-triglyceride breath tests were performed in 5.2% of the patients with 3.5% positivity in the time interval under investigation.

Conservative therapy (QoD: 98%)
131 patients (57%) received enzyme substitution. 71% of the diabetic patients were treated with insulin, 25% with oral antidiabetic drugs and 4% with both. 28 patients (12.5%) required pain killers after discharge.

Endoscopic intervention
Endoscopic treatment was performed in 74 patients (32%) on admission. Endobiliary stents were implanted in 52% of all endoscopic interventions: of those, a single plastic stent was implanted in 50%, multiple plastic stents in 42.1%, a metal stent in 5.3% and a covered metal stent in 2.6% (QoD: 97%). 36.1% of the patients underwent ERCP-EST, 8.3% were treated with main pancreatic duct stenting, 1.3% received both pancreatic duct and biliary stents, and 4.1% had endoscopic pseudocyst drainage. In the endoscopically treated group, endoscopic re-intervention was required in 23% of the cases (QoD: 58%), while the ratio of further surgical intervention was 44% (QoD: 86%) (Tables 3 and 4).

Table 3. Endoscopic treatment.

| Type of intervention (QoD: 97%) | Number of patients (n) | Percentage (%) |
|--------------------------------|------------------------|----------------|
| ERCP-EST                       | 26                     | 36.1           |
| Endobiliary stent              | total 38               | 52             |
| Single plastic stent           | 19                     | 50             |
| Multiple plastic stent         | 16                     | 42.1           |
| Metal stent                    | 2                      | 5.3            |
| Covered metal stent            | 1                      | 2.6            |
| Wirsung duct stent             | 6                      | 8.3            |
| Wirsung and endobiliary stent  | 1                      | 1.3            |
| Pseudocyst drainage            | 3                      | 4.1            |

Table 4. Endoscopic complications.

| Type of complication (ENDOSCOPY) | Number of patients (n) | Percentage (%) |
|---------------------------------|------------------------|----------------|
| Early complications (QoD: 77%)  | bleeding 4             | 7              |
| Re-intervention needed (QoD: 100%) | total 12           | 31.6           |
|                                 | stent removal 5        | 35.7           |
|                                 | stent exchange 3        | 21.4           |
| Late complications              | pseudocyst formation 10 | 15.2           |
| Pancreatic (QoD: 99%)           | pancreatic fistule formation 2 | 3    |
|                                 | acut exacerbation 1     | 1.5            |
|                                 | necrosis/abscess 1      | 1.5            |
|                                 | pancreatic duct obstruction 5 | 7.6   |
|                                 | no complications 47     | 71.2           |
| Biliary (QoD: 100%)             | biliary obstruction 17  | 23             |
|                                 | cholangitis 3           | 4              |
|                                 | no complications 54     | 73             |

doi:10.1371/journal.pone.0171420.t003
doi:10.1371/journal.pone.0171420.t004
Surgery

Surgery was performed in 49 patients (22%) from among the population under investigation in the period under examination (QoD: 100%). Pancreatic decompression was administered in 23.4% of the cases, while surgical drainage was done in 8% in cases where endoscopic drainage was not feasible or in one or two failed endoscopic attempts. The ratio of pancreatic organ-sparing resection was 32%. Bilio-digestive anastomosis was carried out in 26% of the patients. Reoperation was required in the postoperative period in one patient (2.4%) (QoD: 84%). The overall early complication rate of surgical interventions was 1.7% (Tables 5 and 6).

Early and late complications of endoscopic treatment

In the period under examination, 7% of the patients experienced bleeding, but 93% had no early complications (QoD: 77%). Due to stent occlusion, stents were removed in 35.7% of the cases and exchanged in 21.4% of them. The ratio of patients who required later stent implantation was 28% (QoD: 100%).

In the majority of patients (47 patients; 64%), there were no pancreatic complications. The most frequent late pancreatic complication was pseudocyst formation in 15.2% of the cases, followed by obstruction of the duct of Wirsung in 7.6%, fistula formation in 3%, and abscess and recurrent acute exacerbations in 1.5% each (QoD: 89%). Biliary obstruction was observed in 17 cases (23%) and cholangitis in three (4%), while 73% of the patients had no late biliary complications (QoD: 100%). As regards distant organ complications, sepsis occurred in 4% of the patients, respiratory distress in 2% and multi-organ failure (MOF) in 1% (QoD: 99%).

Early and late complications of surgical treatment

Of the 49 operations performed, only one anastomosis leakage was recorded; other non-detailed early complications occurred in three cases on according to admission records.

Table 5. Surgical treatment.

| Type of surgery (QoD: 100%) | Number of patients (n) | Percentage (%) |
|-----------------------------|------------------------|----------------|
| Pancreatic decompression    | 11                     | 23.4           |
| Surgical drainage          | 4                      | 8              |
| Organ sparing resection     | 17                     | 32             |
| Bilio digestive anastomosis | 12                     | 26             |
| Other                       | 5                      | 10.6           |

doi:10.1371/journal.pone.0171420.t005

Table 6. Surgical complications.

| Type of complication (SURGERY) | Number of patients (n) | Percentage (%) |
|-------------------------------|------------------------|----------------|
| **Early complications (QoD: 22%)** |                        |                |
|                               | 4                      | 8              |
| **Late complications**        |                        |                |
| Pancreatic (QoD: 84%)         |                        |                |
| pseudocyst formation          | 9                      | 22             |
| acute exacerbation             | 4                      | 9.7            |
| necrosis/abscess              | 4                      | 9.7            |
| pancreatic duct obstruction   | 2                      | 4.9            |
| no complication               | 22                     | 53.7           |
| Biliary (QoD: 100%)           |                        |                |
| biliary obstruction           | 2                      | 4              |
| no complication               | 47                     | 96             |

doi:10.1371/journal.pone.0171420.t006
Pancreatic pseudocyst formation was also the most frequent late complication in nine patients (22%), followed by acute exacerbations and necrosis/abscess formation in four each (9.7% each) and main pancreatic duct obstruction in two (4.9%). In 53.7% of the population under investigation that underwent surgical intervention, there were no late complications (QoD: 84%). Biliary obstruction was observed in two patients (4%), while there were no late biliary complications in 96% of them (QoD: 100%). Sepsis occurred in one patient (2%), while MOF and respiratory complications were noted in two each (4% each) (QoD: 100%).

Correlations between alcohol consumption and the course of the disease

In the population under examination, patients who consumed alcohol regularly were more likely to have a previous acute exacerbation (76.3% vs. 67.5%) compared to abstinent patients, but the difference was not significant (p = 0.174). The incidence of exocrine insufficiency (58.99% vs. 58.33%, p = 0.923) and diabetes mellitus (38.46% vs. 38.82%, p = 0.821) did not differ significantly in the groups under examination; however, blood sugar level measured on admission was slightly higher in patients who consumed alcohol regularly (8.61 vs. 7.39 mmol/l, p = 0.383, QoD: 62–67%). BMI showed almost the same value in the groups under investigation (22.11 vs. 21.69, p = 0.622, QoD: 69–78%).

In the period under examination, there was not significantly more endoscopic intervention required in patients who drank alcohol (32.9% vs. 32.1%), but, surprisingly, further surgical intervention was needed after endoscopy in more of those patients than among abstinent patients (57.9% vs. 36%, p = 0.089). There was no significant difference (p = 0.636, QoD: 70–85%) in the number of early complications, such as bleeding (3 vs. 1%) or perforation (0 vs. 0%), associated with endoscopy. The number of re-interventions needed during hospitalization was also statistically identical.

Patients who drink alcohol underwent surgery more often (23% vs. 9.8%, p = 0.233). There was no difference in the rate of early complications.

The late complications related to endoscopy (pancreatogenic: 26.83% vs. 36%, p = 0.432, QoD: 87–93%); biliary: 23.4 vs. 29.63%, p = 0.792; sepsis-MOF: 8.7 vs. 7.41%, p = 1) showed no difference with regard to regular alcohol consumption. After surgery, biliary obstruction (3.13 vs. 7.145%, p = 0.521) and severe complications resulting in injury to other organs (6.25 vs. 21.43%, p = 0.157) were similar with no significant difference. Surprisingly, pancreatogenic complications (recurrent acute exacerbations, fistula formation, pancreatic duct obstruction, pseudocyst formation, necrosis/abscess) proved to be higher in abstinent patients compared with patients who consumed alcohol.

Dividing the alcohol-consuming patients into three subgroups – 1–9U/day, 10–19U/day and >19U/day–according to the amount of alcohol consumed, we examined any correlation between the dose of alcohol and the course of the disease (QoD: 35.66%). Hospitalization due to acute exacerbations correlated with the dose of alcohol consumption (63.16 vs. 76.19 vs. 87.5%, p = 0.388). Because of the low number of available data, it was not possible to confirm any further correlation (Fig 1A).

Correlations between smoking and the course of the disease

Patients who smoked regularly were more likely to have a previous acute exacerbation (75% vs. 70.5%) in their anamnesis compared to non-smoking patients with no significant difference (p = 0.48). Incidence of exocrine insufficiency (58.99% vs. 55.42%, p = 0.56) and diabetes mellitus (36.36% vs. 43.37%, p = 0.566) did not differ significantly in the groups under examination, while blood sugar level measured on admission was slightly higher in smoking patients.
Fig 1. Correlations between alcohol consumption (A), smoking (B), smoking with alcohol consumption (C) and the course of the disease: prevalence of acute exacerbation; hospitalisation due to endoscopic intervention; need for further surgery after endoscopic intervention; hospitalisation due to surgery.

doi:10.1371/journal.pone.0171420.g001
(8.37 vs. 7.39 mmol/l, p = 0.664, QoD: 65–69%). BMI showed a non-significant difference in the groups under examination (21.57 vs. 22.52, p = 0.304, QoD: 71–72%).

In the period under examination, smoking patients did not need more endoscopic intervention (32.9% vs. 32.5%), but significantly more further surgical intervention (66.7% vs. 26.9%, p = 0.002) was required following endoscopic treatment than in the case of non-smokers.

During the study period, significantly more surgical interventions were observed in smoking patients (27.3% vs. 10.8%, p = 0.004) than in non-smokers.

There was no significant difference in early and late complications after endoscopy or surgery in the groups under examination (Fig 1B).

**Correlations between smoking, alcohol consumption and the course of the disease**

In the population under investigation, the patients who smoked and consumed alcohol regularly were more likely to have had previous acute exacerbations (76.19 vs. 67.31%, p = 0.237) than non-smoking and abstinent patients. Incidence of enzyme substitution therapy (57.8 vs. 53.57%, p = 0.604) did not differ significantly in the groups under examination, while blood sugar level measured on admission was slightly higher in smoking and alcohol-consuming patients (8.78 vs. 7.52 mmol/l, p = 0.522, QoD: 62–63%). However, significantly more patients suffered from diabetes mellitus (treated with insulin: 22.12 vs. 10.71%, p < 0.001; treated with OAD: 64.6 vs. 26.79%, p < 0.001) in the smoking and alcohol-consuming group compared to the abstinent group.

BMI showed a non-significant difference in the groups under investigation (21.71 vs. 22.01, p = 0.792, QoD: 77–78%). In the period under examination, similar ratios of smoking and alcohol-consuming patients needed endoscopic intervention (33.63 vs. 32.14%, p = 0.847) compared to non-smoking and abstinent patients; however, significantly more patients required further surgical intervention after endoscopy (71.43 vs. 27.78%, p = 0.004). There was no significant difference in the number of early complications, such as bleeding or perforation associated with endoscopy, and the number of re-interventions needed during hospitalization. Similarly, no significant difference was observed in late complications.

Smoking and alcohol-consuming patients had surgery significantly more often (30.09 vs. 12.5%, p = 0.012) than non-smoking and non-drinking patients (Fig 1C).

**Correlations between endocrine and exocrine insufficiency and the course of the disease**

We examined whether diabetes mellitus and known exocrine insufficiency treated with enzyme substitution resulted in a significant influence on the course of the disease. We could not prove any tendency or significant difference between the groups under examination either related to enzyme substitution or to diabetes mellitus. The rate of acute exacerbations (DM: p = 0.247; enzyme substitution: p = 0.439), endoscopic interventions (DM: p = 0.106; enzyme substitution: p = 0.97), surgery (DM: p = 0.721; enzyme substitution: p = 0.481), and complications proved to be identical without any tendency.

**Discussion**

There are very limited data available on the aetiology, symptoms, management and outcome of CP in Hungary. This cohort in CP is the first attempt to collect generally valid data on the epidemiology, diagnosis and treatment of the disease, using data from patient uploads based
on enthusiasm but not obligation on the part of Hungarian pancreatologists. However, epidemiological data may be collected from a single record for the patient. Due to the chronic behaviour of the disease, relevant information on the appropriate treatment, possible complications and course of the disease can be obtained from substantial records of repeated meetings with the patient. This thorough patient follow-up needs to be developed in the future. In this cross-sectional study, we presented the initial data on the first Hungarian cohort in chronic pancreatitis. Without knowing the epidemiological data in Hungary and ensuring a comprehensive patient enrolment, we would be hard-pressed to assert that these data represent the Hungarian population well. However, after the national centres are linked, the database will cover the population with increasing precision. In order to be able to process the data thoroughly, we used the term quality of data (QoD) described above. Nevertheless, with the known limitations, the study provides a good reflection of the course of the disease and the difficulties of diagnosis and treatment in Hungary.

According to various studies, the incidence of CP varies from 4/100,000 in the US [3] to 13.4/100,000 in Finland [4]. The incidence is 11.9/100,000 in Japan [5], 10/100,000 in Denmark [6], 6.4/100,000 in Germany [7], 7.7/100,000 in France [8] and 7.8/100,000 in the Czech Republic [9]. The limits of epidemiological surveys derive from the need for long-term follow-up and the variability of the severity of the disease [10]. The median survival time in alcoholic CP is 20–24 years after the onset of the disease [11]. Unfortunately, there is no current data on the incidence and median survival time for CP in Hungary.

There is evidence of a correlation between CP and pancreatic cancer (PC). Besides the fact that smoking and drinking could be an independent risk factor for pancreatic cancer, it has been demonstrated that in the case of clinically proven CP, the risk for PC is higher than in the average population [12]. According to HPSG multicentre data collection and analysis of pancreatic tumours (PC), the ratio of the presence of CP in the case of PC was 3.7% [13]. As discussed previously, the cross-sectional CP cohort does not contain data on follow-ups. Further development of the registry and ongoing prospective data collection may allow us to obtain valuable information on that topic. Although the cause of CP is regarded as a multifactorial disease [14], the most significant cause of chronic pancreatitis in adult patients is alcohol consumption, except in South India and China, where idiopathic pancreatitis was the most common cause [15]. A multicentre study from Italy showed that 34% of CP cases were caused by excessive alcohol consumption [16]. That figure was 65.4% in the Czech Republic [9], 44% in the US, 95% in Australia and 54% in Japan [15]. In the Hungarian cohort, total alcohol-related CP was 62% (45% of all CP cases consumed alcohol regularly and 18% admitted to occasional alcohol use). This number roughly correlates with other national studies, but it is important to note that some patients may hide their alcohol consumption habit because of its social effects.

Smoking was proved to be another risk factor for CP [17-20], and it seems to reinforce the toxic effect of alcohol in the pancreas [19, 21]. However, other studies suggest that cigarette smoking alone is a risk factor [22]. In our study, 63% of patients still smoked regularly (25% smoked more than 20 cigarettes/day, 32% 10–20 cigarettes/day, and 6% fewer than 10 cigarettes/day), which is a higher percentage than in the normal population in Hungary (32.3% of males and 23.5% of females were smokers in Hungary in 2012).

The role of smoking and alcohol consumption as risk factors for developing CP is well-examined, although the effect on the course of the disease is still unclear. Studies have shown that continuous smoking increases the risk of pancreatic calcification [23] in alcohol-related [19, 24] and idiopathic chronic pancreatitis [20, 25]. A Spanish study from 2014 found an association between tobacco usage and pancreatic exocrine insufficiency in CP [23]. In our study, we established no significant difference between smokers and non-smokers in the need for pancreatic enzyme substitution therapy (59% and 55.4%). Studies found no association
between alcohol consumption and pancreatic calcification [23, 24], but demonstrated that cessation of alcohol reduces pain [26]. Abstinence decreased the number of acute exacerbations in CP [27]. In our study, patients who consumed alcohol regularly were more likely to have experienced previous acute exacerbation compared to abstinent patients. Our study showed that alcohol and tobacco usage alone increased the number of acute exacerbations and the need for endoscopic interventions and surgery and that more patients were referred for further surgical interventions after endoscopic treatment. Combined alcohol consumption and smoking significantly increased the risk of the need for more invasive therapy, suggesting the reinforcing effect of these exogenic factors. Diabetes mellitus is also more frequently present in these patients. In line with our results, Pan et al. showed that the risk of developing DM in patients with CP is influenced by modifiable factors, including alcohol abuse and distal pancreatectomy. It would be interesting to find correlations between the dose of alcohol and the course of the disease. Regrettably, due to the low amount of available data, we could not detect any statistically meaningful correlations. With further improvement to our registry, more thorough data collection is anticipated. However, to identify patients with familial CP—similarly to autoimmune pancreatitis—and find correlations with the other etiologies would be fruitful in term of early diagnosis of these patients, our cross-sectional cohort does not contain enough valid data for that analysis. The improved prospective data collection will open the door for more detailed investigations.

Pain is the hallmark symptom of CP, usually epigastric radiation to the back or to the left upper abdomen, and it is the most common cause of clinical admission [28]. In our cohort, 68% of the patients suffered from pain; in other studies, this varies between 80% and 96% [29–32].

In stage B of chronic pancreatitis, development of common bile duct stricture (CBS) is expected in 3–46% of cases [33–40]; in our cohort, 11% of the patients suffered from jaundice.

Exocrine insufficiency characterized by steatorrhea and loss of weight occurs in end-stage pancreatitis in approximately 30% of cases [41, 42]. 35% of the patients in our study reported significant weight loss, and diarrhoea was recorded in 12.66% of the cases. However, a distressingly low portion of patients were examined with a functional test (5.2%). Endocrine insufficiency was observed in 33% of our cohort, while another study showed 50–75% [43]. However, this is probably a lower percentage than the actual numbers [44].

Diagnosing CP can be challenging, especially in the early stages, because sometimes no radiomorphological signs or laboratory abnormalities can be found. In our cohort, the typical abnormalities were found in 83–86% of the patients, depending on the imaging modality. There is a broad spectrum of imaging techniques that can be used. Transabdominal ultrasound (US) is a relatively cheap, easily accessible, non-invasive and rapid diagnostic tool. It can be employed to detect pancreatic calcifications, pseudocysts and complications of CP, such as common bile duct obstruction and splenic or mesenteric vein obstruction. Unfortunately, bowel gas and body composition can make the process difficult, and there is no correlation between pancreatic exocrine function and the number of calcifications [45]. The sensitivity of transabdominal US is between 60 and 81%, while specificity is between 70 and 97% [46–48]. In our cohort, US was performed in 80% of the patients. Computed tomography is regarded as one of the best initial imaging tests. It is widely available and permits a detailed evaluation of pancreatic parenchyma, helping rule out pancreatic malignomas. CT is superior to US in detecting pseudocysts and complications of CP. The sensitivity and specificity of CT are 75–90% and 80%, respectively [49]. ERCP was long the gold standard for CP diagnosis and staging, with sensitivity of 70–95% and specificity of 90% or more, but with a significant morbidity (3 to ≥40%) and mortality (0.1–1%) [50]. It is therefore no longer employed as a diagnostic tool. MRCP is a non-invasive imaging test, which does not use ionizing radiation and provides
an excellent image of the main pancreatic duct, with sensitivity of 88% and specificity of 98% [51]. Secretin-enhanced MRCP allows for a quantitative assessment of exocrine pancreatic function by measuring the duodenal filling [52] and provides a more accurate way to identify small-duct disease in mild chronic pancreatitis [53]. The Hungarian Pancreatic Study Group (HPSG) prepared an evidence-based guideline for CP, which does not recommend the use of the ERCP as a diagnostic tool because of its morbidity and mortality rates. Unfortunately, 39% of participating patients underwent diagnostic ERCP. Endoscopic ultrasound (EUS) is a very sensitive diagnostic tool, allowing for the evaluation of the pancreatic parenchyma and duct system with sensitivity and specificity of 80–100% [54], but it is observer-dependent and has a tendency toward over-diagnosis [55]. Unfortunately, EUS was used in only 7.4% of all patients in our cohort, a result explained by the still low number of imaging devices in the country.

However, the diagnosis of chronic pancreatitis is mainly based on imaging techniques, while functional tests can be helpful in inconclusive cases. The fact that neither indirect nor direct functional tests are widespread and available in Hungarian centres has resulted in the fact that only 5.2% of the entire population under examination had undergone any kind of functional testing. Despite poor functional testing for CP, enzyme substitution was administered in 57% of the patients based on clinical symptoms and radiomorphological changes. Steatorrhea only occurs when lipase secretion is ≤ 10% [56]. It is important to distinguish between pancreatic exocrine insufficiency and CP as up to 20% of CP cases with exocrine insufficiency presented with no history of pain [57]. In Hungarian clinical practice, enzyme substitution therapy is reimbursed in the presence of steatorrhea or maldigestion. In our study, 52% of the patients received enzyme substitution therapy.

The therapy for chronic pancreatitis is complex and based on lifestyle changes. In the case of alcoholic CP, complete elimination of alcohol reduces the pain [26] in 50% of patients [58], and there is increasing evidence that tobacco use plays an important role in CP [19]. In our cohort, we have no information on how many of our patients remained abstinent and/or stopped smoking and how this affected their quality of life. Pain is a major clinical problem in CP patients. Worldwide, pain management follows the WHO “pain relief ladder” recommendation; in our study, 12.5% of all the patients required continuous analgesia and 87.4% took painkillers episodically. Unfortunately, we have no information on the kinds of drugs they used.

Managing CP patients is a complex task; treatment requires different strategies depending on the stage, aetiology, morphological changes and various symptoms of the disease. Basically, the treatment requires a multidisciplinary consensus.

Endoscopic intervention may be feasible for the drainage of pancreatic pseudocysts and jaundice caused by CBS as well as for main pancreatic duct calcifications with proximal juxtapapillary stenosis. In pain management, endoscopic treatment showed good results for short-term symptomatic disease (≤ 4 years), if there was no pancreatic duct stricture and if obstructive calcifications were restricted to the pancreatic head [59]. Besides the latter, there are two groups of patients where primary endoscopic treatment seems to be a better choice than surgery: children with hereditary pancreatitis [60] and patients who have portal vein thrombosis and are unfit for surgery [30]. The indication for pseudocyst endoscopic drainage is a symptomatic disease (pain, abdominal discomfort, CBS and gastric outlet syndrome), 3–6 months’ wait-and-see after the diagnosis and a minimum size of 3cm [61]. Long-term clinical success may be 70–90% [62]. In our cohort, endoscopic pseudocyst drainage was done in 4.17% of the patients and two out of three patients had recurrent pseudocysts as a late complication. In our study, endobiliary stent implantation was performed in 52% of the patients (50% of these interventions involved a single plastic stent, 42.1% multiple plastic stents, 5.3% a self-expandable metal stent and 2.6% a covered metal stent). An endoscopic stent implant of longer
than 12 months—particularly in the case of calcification in the pancreatic head—is inferior to surgery. It only provides a short-term solution, the long-term success rate is poor and only one out of four strictures is treated effectively with this method [63]. Obstructive jaundice recurs in up to 88% of cases [62] and with the presence of pancreatic head calcification the risk of failure is 17-fold (95%) in a twelve-month period. During the median follow-up, 49.2% of the patients required surgical intervention after endoscopic stent implantation [64]. Bilio-digestive anastomosis during surgery provides a better result; only 18% of the patients developed stricture after the operation [65]. In our study, 23% of all patients needed further stent implantation (QoD: 58%). More importantly, a high number of patients (44%) required surgical intervention after endoscopic biliary drainage, indicating the priority of surgical procedures in chronic pancreatitis with biliary obstruction.

Pain, the hallmark symptom of CP, is the major indication for surgery, which is the most effective long-term form of pain therapy for chronic pancreatitis. Two randomized controlled studies provided significantly better pain management with surgical intervention involving a pancreatojejunostomy than with endoscopic treatment [66] [67]. 97% of patients with CP may suffer from abdominal pain, between 35% and 49% experience CBS, and between 6% and 12% have duodenal stenosis [68, 69]. In our cohort, pain occurred in 68% of the cases and CBS in 11%, but, unfortunately, we have no information on DS. The goals of surgical interventions besides pain relief are to preserve as much functional pancreas tissue as possible by correcting anatomical changes such as CBS and DS. In CP, the source of pain can stem from two sources: parenchymal compression due to the obstructed pancreatic duct system and the alteration of intrapancreatic nerve fibres and the activation state of intrapancreatic glia due to chronic inflamed pancreatic tissue, especially in the pancreatic head. The head is considered the pace-maker of pain, causing neuropathic pain and visceral neuropathy [70]. As we noted before, endoscopic pseudocyst drainage is recommended, unless the anatomical situation or the cyst content does not allow such an intervention. The aim of surgical drainage procedures is the drainage and decompression of pancreatic tissue due to the obstructed pancreatic duct system. The first method was described by Duvall in 1953: pancreatic tail resection and splenectomy with retrograde drainage of the main duct into a defunctioning jejunal loop. In 1958, the Puestow–Gillesby modification added a longitudinal opening of the pancreatic duct to the Duvall procedure and achieved wider drainage of the pancreatic duct system. The Partington–Rochelle procedure consists of a side-to-side lateral pancreatojejunostomy, without a pancreatic tail and spleen resection, sparing pancreatic tissue and preventing endocrine and exocrine pancreatic insufficiency. The procedure relieves chronic abdominal pain in 66–91% of cases with a mean follow-up of 3.5–9.1 years; unfortunately, 30% of patients experience no pain relief due to the chronic inflamed pancreatic head [71]. In our study, 8% of the patients underwent a drainage procedure, but we do not know the pain recurrence rate in the absence of long-term follow-up. The inflamed, enlarged pancreatic head mass causes CDS and DS. Pancreaticoduodenectomy (PD) was the only solution until 1972, when Beger described the duodenum-preserving pancreatic head resection (DPPHR). In this procedure, the stomach, the duodenum and the extrahepatic bile ducts are spared. With the decompression of the intrapancreatic common bile duct and the resection of the inflamed pancreatic head, the common bile duct can be opened and sutured to the bottom of the resected cavity [72]. In 1987, Frey and Smith developed a hybrid DPPHR adding a LPJ. The Berne modification to the Beger procedure avoids the transection of the pancreas, instead performing a scoop-like pancreatic head resection with one pancreatojejunostomal anastomosis. In the case of the Beger procedure, after a median follow-up of 5–7 years, less than 10% of patients experienced recurrent pain [73]. In contrast, 75% of patients were pain-free with the Frey procedure with a follow-up of 3–4 years, but 13% experienced no pain relief [74]. Compared to PD, DPPHR is equally effective in terms...
of postoperative pain relief, overall morbidity and incidence of postoperative endocrine insufficiency [75]. A metaanalysis from 2015 compared the Frey and Beger procedures, and pain relief was achieved in 89% of cases using the Frey procedure in PD with a shorter operation time and lower overall morbidity [76]. 18% of patients who had undergone DPPHR developed a stricture in the reinsertion site, while it was only 4% in PD [65]. If DS is present or the probability of malignancy occurs, standard PD is recommended. In our study, the rate of pancreatic resection was 32%, pancreatic decompression was 23.4%, surgical drainage was 8% and biliodigestive anastomosis construction was 26% with an acceptable early complication rate and rate of required reoperation in the early postoperative period as well as a definitely smaller complication rate on the biliary tract, compared to endoscopic interventions.

Conclusions
Chronic pancreatitis should be treated by multidisciplinary consensus using evidence-based medicine. Data should be revised continuously in accordance with the chronic nature of the disease. Conclusions from the first nationwide prospective data collection effort in Hungary provide important information to improve treatment of the disease and define the role of endoscopy and surgery. However, the quality of data collection requires further development with improvement to the registry. In our cohort, (1) the epidemiological data are comparable to international studies. (2) The aetiological factors differ little from European trends. (3) The number of times diagnostic ERCP is used should be reduced, while use of EUS should be increased. (4) Our results proved that alcohol consumption and smoking represent a risk factor for the increased need of surgical intervention, suggesting that the elevated number of patients cannot be treated with conservative and less invasive endoscopy. (5) The role of surgery in the treatment of chronic calcifying pancreatitis with biliary obstruction should be highlighted. Future plans by the Hungarian Pancreatic Study Group include improving the quality of data collection and expanding the database to other Central and Eastern European countries.

Supporting information
S1 Table. Data of alcohol consumption, smoking, smoking with alcohol consumption, dose of alcohol, enzyme substitution and diabetes mellitus.
(XLSX)

Acknowledgments
This study was supported by the Hungarian Scientific Research Fund (K116634 to PH) and the Momentum Grant from the Hungarian Academy of Sciences (LP2014-10/2014 to PH).

List of the author group: Ákos Szűcs, Tamás Marjai, Andrea Szentesi, Nelli Farkas, Andrea Párticszy, György Nagy, Balázs Kui, Tamás Takács, László Czakó, Zoltán Szepes, Balázs Csaba Németh, Aron Vincze, Gabriella Pár, Imre Szabó, Patrícia Sarlós, Anita Illés, Szilárd Gödi, Ferenc Ibéki, Judit Gervain, Adrienn Halász, Gyula Farkas, László Leindler, Dezső Kelemen, Róbert Papp, Richárd Szimola, Mára Varga, József Hamvas, János Novák, Barnabás Bod, Miklós Sahin-Tóth and Péter Hegyi.

The authors wish to thank other contributors for their work, including Csilla Andorka (First Department of Paediatrics, Semmelweis University, Budapest, Hungary), Adrienn Csiszó (Institute of Surgery, Clinical Centre, University of Debrecen, Debrecen, Hungary), Tamás Forster (Second Department of Medicine, University of Szeged, Szeged, Hungary), András Gelléy (Department of Internal Medicine and Gastroenterology, Polyclinic of
Hospitaller Brothers of Saint John of God, Budapest, Hungary), Csaba Gőg (Healthcare Centre of Csongrád County, Makó, Hungary), György Kovács (Second Department of Internal Medicine, University of Debrecen, Debrecen, Hungary), Eszter Schafer (Department of Gastroenterology, Medical Centre of the Hungarian Defence Forces, Budapest, Hungary), János Sümegi (Borsod-Abáuj-Zemplén County Hospital and University Teaching Hospital, Miskolc, Hungary), Zsolt Szentkereszty (Institute of Surgery, Clinical Centre, University of Debrecen, Debrecen, Hungary), and Attila Szepes (Bács-Kiskun County University Teaching Hospital, Kecskemét, Hungary).

Author Contributions

Conceptualization: Á. Szűcs PH.

Data curation: NF.

Formal analysis: Á. Szűcs TM A. Szentesi, NF AP GN BK TT LC ZS BCN AV GP IS PS AI SG FI JG AH GF LL DK RP RS MV JH JN BB.

Investigation: Á. Szűcs TM PH.

Methodology: Á. Szűcs PH.

Resources: PH.

Supervision: Á. Szűcs PH MST.

Validation: Á. Szűcs TM PH.

Visualization: Á. Szűcs TM PH.

Writing – original draft: Á. Szűcs TM PH.

Writing – review & editing: Á. Szűcs PH.

References

1. Buchler MW, Martignoni ME, Friess H, Malfertheiner P. A proposal for a new clinical classification of chronic pancreatitis. BMC Gastroenterol. 2009; 9:93. doi: 10.1186/1471-230X-9-93 PMID: 20003450

2. Layer P, Keller J. Lipase supplementation therapy: standards, alternatives, and perspectives. Pancreas. 2003; 26(1):1–7. PMID: 12499909

3. Yadav D, Timmons L, Benson JT, Dierkhising RA, Chari ST. Incidence, prevalence, and survival of chronic pancreatitis: a population-based study. Am J Gastroenterol. 2011; 106(12):2192–9. doi: 10.1038/ajg.2011.328 PMID: 21946280

4. Jaakkola M, Nordback I. Pancreatitis in Finland between 1970 and 1989. Gut. 1993; 34(9):1255–60. PMID: 8406164

5. Hirota M, Shimosegawa T, Masamune A, Kikuta K, Kume K, Hamada S, et al. The sixth nationwide epidemiological survey of chronic pancreatitis in Japan. Pancreatology. 2012; 12(2):79–84. Epub 2012/04/11. doi: 10.1016/j.pan.2012.02.005 PMID: 22487515

6. Andersen BN, Pedersen NT, Scheel J, Warming H. Incidence of alcoholic chronic pancreatitis in Copenhagen. Scand J Gastroenterol. 1982; 17(2):247–52. PMID: 7134849

7. Lankisch PG, Assmus C, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic diseases in Luneburg County. A study in a defined german population. Pancreatology. 2002; 2(5):469–77. doi: 10.1159/000064713 PMID: 12378115

8. Levy P, Bartheil M, Mollard BR, Amouretti M, Marion-Audibert AM, Dyard F. Estimation of the prevalence and incidence of chronic pancreatitis and its complications. Gastroenterol Clin Biol. 2006; 30(6–7):836–44. PMID: 16885967

9. Dite P, Stary K, Novotny I, Precechtelova M, Dolina J, Lata J, et al. Incidence of chronic pancreatitis in the Czech Republic. Eur J Gastroenterol Hepatol. 2001; 13(6):749–50. PMID: 11434607
10. Levy P, Dominguez-Munoz E, Imrie C, Lohr M, Maisonneuve P. Epidemiology of chronic pancreatitis: burden of the disease and consequences. United European Gastroenterol J. 2014; 2(5):345–54. doi: 10.1177/2050640614548208 PMID: 25360312

11. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, et al. Prognosis of chronic pancreatitis: an international multicenter study. International Pancreatitis Study Group. Am J Gastroenterol. 1994; 89(9):1467–71. PMID: 8079921

12. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002; 51(6):849–52. PMID: 12427788

13. Lakatos G, Balazs A, Kui B, Godi S, Szucs A, Szentesi A, et al. Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group. J Gastrointestin Liver Dis. 2016; 25(2):219–25. doi: 10.15403/jgld.2014.1121.252.pcr PMID: 27308654

14. Schneider A, Lohr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. J Gastroenterol. 2007; 42(2):101–19. doi: 10.1007/s00535-006-1945-4 PMID: 17351799

15. Yadav D, Whitcomb DC. The role of alcohol and smoking in pancreatitis. Nat Rev Gastroenterol Hepatol. 2010; 7(3):131–45. doi. 10.1038/nrgastro.2010.6 PMID: 20125091

16. Frulloni L, Gabbielli A, Pezzilli R, Zerbi A, Cavestro GM, Marotta F, et al. Chronic pancreatitis: report from a multicenter Italian survey (PanCroInfAIS P) on 893 patients. Dig Liver Dis. 2009; 41(4):311–7. doi: 10.1016/j.dld.2008.07.316 PMID: 19097829

17. Jianyu H, Guang L, Baosen p. Evidence for cigarette smoke-induced oxidative stress in the rat pancreas. Inhal Toxicol. 2009; 21(12):1007–12. doi: 10.1080/08958370802665937 PMID: 19635036

18. Wittel UA, Hopt UT, Batra SK. Cigarette smoke-induced pancreatic damage: experimental data. Langenbecks Arch Surg. 2008; 393(4):581–8. doi: 10.1007/s00423-007-0273-3 PMID: 18193450

19. Maisonneuve P, Lowenfels AB, Mullhaupt B, Cavallini G, Lankisch PG, Andersen JR, et al. Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. Gut. 2005; 54(4):510–4. doi: 10.1136/gut.2004.039263 PMID: 15753536

20. Imoto M, DiMagno EP. Cigarette smoking increases the risk of pancreatic calcification in late-onset but not early-onset idiopathic chronic pancreatitis. Pancreas. 2000; 21(2):115–9. PMID: 10975703

21. Rebours V, Vullierme MP, Hentic O, Maire F, Hammel P, Ruszniewski P, et al. Smoking and the course of recurrent acute and chronic alcoholic pancreatitis: a dose-dependent relationship. Pancreas. 2012; 41(8):1219–24. doi: 10.1097/MPA.0b013e31825de97d PMID: 23066245

22. Talamini G, Bassi C, Falconi M, Frulloni L, Di Francesco V, Vaona B, et al. Cigarette smoking: an independent risk factor in alcoholic pancreatitis. Pancreas. 1996; 12(2):131–7. PMID: 8720658

23. Luaces-Regueira M, Iglesias-Garcia J, Lindkvist B, Castineira-Alvarino M, Nieto-Garcia L, Larino-Noia J, et al. Smoking as a risk factor for complications in chronic pancreatitis. Pancreas. 2014; 43(2):275–80. doi: 10.1097/MPA.0b013e32835f2f6d PMID: 24518508

24. Cavallini G, Talamini G, Vaona B, Bovo F, Filippini M, Rigo L, et al. Effect of alcohol and smoking on pancreatic lithogenesis in the course of chronic pancreatitis. Pancreas. 1994; 9(1):42–6. PMID: 8108370

25. Maisonneuve P, Frulloni L, Mullhaupt B, Faitini K, Cavallini G, Lowenfels AB, et al. Impact of smoking on patients with idiopathic chronic pancreatitis. Pancreas. 2006; 33(2):163–8. doi: 10.1097/01.mpa.0000227916.94073.fc PMID: 16868482

26. Pelli H, Sand J, Nordback I. [Can the recurrence of alcohol-induced pancreatitis be prevented?]. Duodecin. 2009; 125(11):1195–200. PMID: 19579980

27. Strum WB. Abstinence in alcoholic chronic pancreatitis. Effect on pain and outcome. J Clin Gastroenterol. 1995; 20(1):37–41. PMID: 7884175

28. Thuluvath PJ, Imperio D, Nair S, Cameron JL. Chronic pancreatitis. Long-term pain relief with or without surgery, cancer risk, and mortality. J Clin Gastroenterol. 2003; 36(2):159–65. doi: 10.1097/01.mja.0000437324.52596.aa PMID: 12454201

29. Ammann RW. The natural history of alcoholic chronic pancreatitis. Intern Med. 2001; 40(5):368–75. PMID: 11393404

30. Braganza JM, Lee SH, McCloy RF, McMahon MJ. Chronic pancreatitis. The Lancet. 377(9772):1184–97.

31. Layer P, DiMagno EP. Early and late onset in idiopathic and alcoholic chronic pancreatitis. Different clinical courses. Surg Clin North Am. 1999; 79(4):847–60. PMID: 10470331

32. Mullady DK, Yadav D, Amann ST, O’Connell MR, Barmada MM, Elta GH, et al. Type of pain, pain-associated complications, quality of life, disability and resource utilisation in chronic pancreatitis: a prospective cohort study. Gut. 2011; 60(1):77–84. doi: 10.1136/gut.2010.213835 PMID: 21148579
33. Yadegar J, Williams RA, Passaro E Jr., Wilson SE. Common duct stricture from chronic pancreatitis. Arch Surg. 1980; 115(5):582–6. PMID: 7377960
34. Petrozza JA, Dutta SK. The variable appearance of distal common bile duct stenosis in chronic pancreatitis. J Clin Gastroenterol. 1985; 7(5):447–50. PMID: 4067233
35. Wisloff F, Jakobsen J, Osnes M. Stenosis of the common bile duct in chronic pancreatitis. Br J Surg. 1982; 69(1):52–4. PMID: 7053803
36. Stabile BE, Calabria R, Wilson SE, Passaro E Jr. Stricture of the common bile duct from chronic pancreatitis. Surg Gynecol Obstet. 1987; 165(2):121–6. PMID: 3603341
37. Huizinga WK, Thomson SR, Spitaels JM, Simjee AE. Chronic pancreatitis with biliary obstruction. Ann R Coll Surg Engl. 1992; 74(2):119–23; discussion 23–5. PMID: 1567130
38. Aranha GV, Prinz RA, Freeark RJ, Greenlee HB. The spectrum of biliary tract obstruction from chronic pancreatitis. Arch Surg. 1984; 119(5):595–600. PMID: 6712475
39. Afroudakis A, Kaplowitz N. Liver histopathology in chronic common bile duct stenosis due to chronic alcoholic pancreatitis. Hepatology. 1981; 1(1):65–72. PMID: 7286890
40. Sand JA, Nordback IH. Management of cholestasis in patients with chronic pancreatitis: evaluation of a treatment protocol. Eur J Surg. 1995; 161(8):587–92. PMID: 8519875
41. Witt H, Apte MV, Keim V, Wilson JS. Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology. 2007; 132(4):1557–73. doi: 10.1053/j.gastro.2007.03.001 PMID: 17466744
42. DiMagno MJ, DiMagno EP. Chronic pancreatitis. Curr Opin Gastroenterol. 2006; 22(5):487–97. doi: 10.1097/MOG.0b013e32839862.96833.89 PMID: 16891879
43. Bank S, Marks IN, Vinik AI. Clinical and hormonal aspects of pancreatic diabetes. Am J Gastroenterol. 1975; 64(1):13–22. PMID: 808121
44. Angelopoulos N, Dervenis C, Goula A, Rombopoulos G, Livadas S, Kaltsas D, et al. Endocrine pancreatic insufficiency in chronic pancreatitis. Pancreatology. 2005; 5(2–3):122–31. doi: 10.1159/000085264 PMID: 15849483
45. Ammann RW, Muench R, Otto R, Buehler H, Freiburghaus AU, Siegenthaler W. Evolution and regression of pancreatic calcification in chronic pancreatitis. A prospective long-term study of 107 patients. Gastroenterology. 1988; 95(4):1018–28. PMID: 3410215
46. Buscaill L, Escourrou J, Moreau J, Delvaux M, Louvel D, Lapeyre F, et al. Endoscopic ultrasonography in chronic pancreatitis: a comparative prospective study with conventional ultrasonography, computed tomography, and ERCP. Pancreas. 1995; 10(3):251–7. PMID: 7624302
47. Glasbrenner B, Kahl S, Malfertheiner P. Modern diagnostics of chronic pancreatitis. Eur J Gastroenterol Hepatol. 2002; 14(9):935–41. PMID: 12352212
48. Hollerbach S, Ruser J, Ochs A, Frick E, Scholmerich J. [Current status of abdominal pancreatic ultrasound. A retrospective analysis of 585 pancreatic ultrasound examinations]. Med Klin (Munich). 1994; 89(1):7–13.
49. Luetmer PH, Stephens DH, Ward EM. Chronic pancreatitis: reassessment with current CT. Radiology. 1989; 171(2):353–7. Epub 1989/05/01. doi: 10.1148/radiology.171.2.2704799 PMID: 2704799
50. Mitchell RMS, Stephen DH, Ward EM. Chronic pancreatitis: reassessment with current CT. Radiology. 1989; 171(2):353–7. Epub 1989/05/01. doi: 10.1148/radiology.171.2.2704799 PMID: 2704799
51. Hoffmeister A, Maye R, Beglinger C, Buchler MW, Bufler P, Dathe K, et al. [S3-Consensus guidelines on definition, etiology, diagnosis and medical, endoscopic and surgical management of chronic pancreatitis]. Z Gastroenterol. 2012; 50(11):1176–224. Epub 2012/11/15. doi: 10.1055/s-0032-1325479 PMID: 23150111
52. DiMagno MJ, DiMagno EP. Chronic pancreatitis. Curr Opin Gastroenterol. 2010; 26(5):490–8. doi: 10.1097/MOG.0b013e32833d11b2 PMID: 20693896
53. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med. 1973; 288(16):813–5. doi: 10.1056/NEJM197304192881603 PMID: 4693931
57. Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology. 1994; 107(5):1481–7. Epub 1994/11/01. PMID: 7926511

58. Lohr JM, Schneider HT. Die natürliche Entwicklung von Schmerzen bei alkoholischer chronischer Pankreatitis. Z Gastroenterol. 2000; 38(07):603–5.

59. Hirota M, Asakura T, Kanno A, Shimosegawa T. Endoscopic treatment for chronic pancreatitis: indications, technique, results. Journal of hepato-biliary-pancreatic sciences. 2010; 17(6):770–5. Epub 2009/10/15. doi: 10.1007/s00534-009-0182-z PMID: 19826752

60. Siddiqui UD, Jamidar PA. Managing complications of hereditary pancreatitis: all roads lead to ERCP. J Clin Gastroenterol. 2010; 44(1):1–2. doi: 10.1097/MCG.0b013e3181bb87f4 PMID: 19834339

61. Andreu-Sandberg A, Dervenis C. Pancreatic pseudocysts in the 21st century. Part I: classification, pathophysiology, anatomic considerations and treatment. Jop. 2004; 5(1):8–24. Epub 2004/01/20. PMID: 14730118

62. Nguyen-Tang T, Dumonceau JM. Endoscopic treatment in chronic pancreatitis, timing, duration and type of intervention. Best Pract Res Clin Gastroenterol. 2010; 24(3):281–98. doi: 10.1016/j.bpg.2010.03.002 PMID: 20510829

63. Cahen DL, van Berkel AM, Oskam D, Rauws EA, Weverling GJ, Huibregtse K, et al. Long-term results of endoscopic drainage of common bile duct strictures in chronic pancreatitis. Eur J Gastroenterol Hepatol. 2005; 17(1):103–8. Epub 2004/01/20. PMID: 14730118

64. Nguyen-Tang T, Dumonceau JM. Endoscopic treatment in chronic pancreatitis, timing, duration and type of intervention. Best Pract Res Clin Gastroenterol. 2010; 24(3):281–98. doi: 10.1016/j.bpg.2010.03.002 PMID: 20510829

65. Cahen DL, Gouma DJ, Nio Y, Rauws EA, Boermester MA, Busch OR, et al. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. N Engl J Med. 2007; 356(7):676–84. doi: 10.1056/NEJMoa060610 PMID: 17301298

66. Vijunco JD, Prinz RA. Management of biliary and duodenal complications of chronic pancreatitis. World J Surg. 2003; 27(11):1258–70. doi: 10.1007/s00268-003-7246-z PMID: 14534824

67. Schoenberg MH, Hepp G, Beger HG. [Duodenum-preserving resection of the pancreas head in treatment of benign tumors of the pancreas head]. Chirurg. 1998; 69(6):633–8. PMID: 9676366

68. Ceyhan GO, Demir IE, Rauch U, Bergmann F, Muller MW, Buchler MW, et al. Pancreatic neuropathy results in "neural remodelling" and altered pancreatic innervation in chronic pancreatitis and pancreatic cancer. Am J Gastroenterol. 2009; 104(10):2555–65. doi: 10.1038/ajg.2009.380 PMID: 19568227

69. Isaji S. Has the Partington procedure for chronic pancreatitis become a thing of the past? A review of the evidence. Journal of hepato-biliary-pancreatic sciences. 2010; 17(6):763–9. Epub 2009/09/26. doi: 10.1007/s00534-009-0181-b PMID: 19779664

70. Beger HG, Krautzberger W, Bittner R, Buchler M, Limmer J. Duodenum-preserving resection of the head of the pancreas in patients with severe chronic pancreatitis. Surgery. 1985; 97(4):467–73. Epub 1985/04/01. PMID: 3983823

71. Beger HG, Buchler M, Bittner RR, Oettlinger W, Roscher R. Duodenum-preserving resection of the head of the pancreas in severe chronic pancreatitis. Early and late results. Ann Surg. 1989; 209(3):273–8. PMID: 2923514

72. Frey CF, Mayer KL. Comparison of local resection of the head of the pancreas combined with longitudinal pancreaticojejunostomy (frey procedure) and duodenum-preserving resection of the pancreatic head (beger procedure). World J Surg. 2003; 27(11):1217–30. doi: 10.1007/s00268-003-7241-z PMID: 14534821

73. Diener MK, Rahbari NN, Fischer L, Antes G, Buchler MW, Seiler CM. Duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for surgical treatment of chronic pancreatitis: a systematic review and meta-analysis. Ann Surg. 2008; 247(6):950–61. doi: 10.1097/SLA.0b013e3181724ee7 PMID: 18520222

74. Zhou Y, Shi B, Wu L, Wu X, Li Y. Frey procedure for chronic pancreatitis: Evidence-based assessment of short- and long-term results in comparison to pancreatoduodenectomy and Beger procedure: A meta-analysis. Pancreatology. 2015; 15(4):372–9. Epub 2015/06/10. doi: 10.1016/j.pan.2015.05.046 PMID: 26055537